INB-03

Company to Host Conference Call Today, May 9, at 4:30pm ETBOCA RATON, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended March 31, 2024 and provides a business update. Q1 2024 and Recent Corporate Highlights DN-TNF Platform Highlights (XPro™): The AD02 randomized, blinded program for patients with Early Alzheimer's Disease remains on schedule to reach its final enrollment target by mid-2024, with top-line data expected to be presented approximately six months after the last patient is enrolled. The trial is currently active in North America, UK, EU, and the Pacific Rim. The Company anticipates having its Phase II FDA meeting in the first half of 2025 before transitioning to the global Phase III trial in the latter portions of next year.The Company successfully completed extended stability validation for XPro™ at continuous storage in solution at 2C-8C. The 24 and 30-month stability test samples passed all chemistry and potency assays allowing the Company to make a conservative claim of 24-month stability and positioning it to meet the dosing demands envisioned in the Phase III trial.On April 30th, the Company issued a press release highlighting the progress of two patients from the Phase 1b AD trial in Australia who have continued to receive XPro™ treatment under an open-label program administered by their treating physician. The testimonials underscore XPro’s™ unique attributes that may prevent progression cognitive impairment versus existing treatments that appears to slow the pace of but do not stop the progression of cognitive dysfunction.INB03 cancer platform – two posters were presented at the annual American Association of Cancer Research in San Diego on April 8, 2024. The posters extends ongoing research led by Roxana Schillaci, Ph.D., of Instituto de Biología y Medicina Experimental in Buenos Aries, Argentina on the importance of MUC4 expression in high-risk breast cancer subtypes is a predictor of progression and resistance to therapy. Tumors that express MUC4 have an unfavorable immunobiology of the tumor microenvironment (TME) and increased metastatic potential all driven by soluble TNF. Neutralization of soluble TNF with INB03 resulted in down-regulation of immune checkpoint proteins on T cells (PD1, TIGIT, LAG3 and CTLA4) and macrophages (CD47 and SIRPꭤ) in the TME. The data suggests testing for MUC4 before treatment will predict resistance to first-line therapy which may allow better treatment choices that may improve patient outcomes. INKmune™ Platform: The first cohort in the Phase I/II open label trial of INKmune™ in metastatic castration-resistant prostate cancer (mCRPC) successfully completed the first dosing. Following review by the Safety Review Committee (SRC), approval was granted to proceed with the second dose level (cohort 2) and two patients have been enrolled. The first patient of the middle dose cohort is expected to be treated this month.Safety of INKmune remains on track. There have been nine administrations of INKmune in the mCRPC study given on an out-patient basis, with no significant adverse events. Combining the experience with INKmune from the MDS/AML and mCRPC trials, over 20 infusions of INKmune have been given safely without the need for conditioning therapy, pre-medication, or cytokine support. Patients receive three infusions of INKmune™ per dosing over two weeks and are monitored for four months for immunological and clinical responses. Three dose levels of INKmune™ are being tested in a modified Bayesian Phase I/II trial. Corporate: The Company successfully raised a combined $14.5 million of equity capital before placement agent fees and expenses in two separate transactions in late April. Of note, in the first $4.8 million offering, management, employees and members of the Board of Directors purchased over 20% of the offering. Excluding shares and warrants acquired by insiders, both offerings were priced at the market. The warrants terminate on the earlier of (1) the two (2) year anniversary of the initial exercise date of the warrant or (2) thirty (30) trading days following the reporting of top line data (EMACC) in the Phase 2 Alzheimer's program of XPro1595, (the “Termination Date”). Should the warrants be exercised for cash, the Company would receive additional funding. Upcoming Events and Milestones: Full enrollment in the Phase II XPro™ trial for treatment of neuroinflammation as a cause of Alzheimer’s Disease are expected mid-2024 followed by top-line data approximately six months from the last patient enrolled.Initiate a Phase II trial of XPro™ in patients with Treatment-Resistant Depression 2H 2024.Expect to complete enrollment in the Phase I portion of the mCRPC trial by end of Q3 2024. The Phase II portion is expected to complete enrollment in Q2, 2025. Because the trial is open-label, we expect to provide periodic data updates on the immunologic and therapeutic response to INKmune in the participants of the CaRePC trial in mCPRC. Financial Results for the First Quarter Ended March 31, 2024: Net loss attributable to common stockholders for the quarter ended March 31, 2024 was approximately $11.0 million, compared to approximately $6.5 million during the quarter ended March 31, 2023.Research and development expenses totaled approximately $8.7 million for the quarter ended March 31, 2024, compared to approximately $4.1 million during the quarter ended March 31, 2023.General and administrative expenses were approximately $2.3 million for the quarter ended March 31, 2024, compared to approximately $2.3 million during the quarter ended March 31, 2023.As of March 31, 2024, the Company had cash and cash equivalents of approximately $26.0 million. Subsequent to the end of the quarter, the Company raised gross proceeds of approximately $16.6 million from the sale of common stock and warrants.As of May 9, 2024, the Company had approximately 19.8 million common shares outstanding. Earnings Call Information To participate in this event, dial approximately 5 to 10 minutes before the beginning of the call. Please ask for the INmune Bio First Quarter Conference Call when reaching an operator. Date: May 9, 2024Time: 4:30 PM Eastern TimeParticipant Dial-in: 1-800-343-5172Participant Dial-in (international): 1-203-518-9856Conference ID: INMUNE A live audio webcast of the call can be accessed by clicking here or using this link:https://viavid.webcasts.com/starthere.jsp?ei=1666877&tp_key=6505d73fc4 A transcript will follow approximately 24 hours from the scheduled call. A replay will also be available through May 15 by dialing 1-844-512-2921 or 1-412-317-6671 (international) and entering PIN no. 1155727. About XPro™ XPro™ is a next-generation inhibitor of tumor necrosis factor (TNF) that is currently in clinical trial and acts differently than currently available TNF inhibitors in that it neutralizes soluble TNF (sTNF), without affecting trans-membrane TNF (tmTNF) or TNF receptors. XPro™ could have potential substantial beneficial effects in patients with neurologic disease by decreasing neuroinflammation. For more information about the importance of targeting neuroinflammation in the brain to improve cognitive function and restore neuronal communication visit this section of the INmune Bio’s website. About INKmune™ INKmune™ is a pharmaceutical-grade, replication-incompetent human tumor cell line which conjugates to resting NK cells and delivers multiple, essential priming signals to convert the cancer patient’s resting NK cells into tumor killing memory-like NK cells (mlNK cells). INKmune™ treatment converts the patient’s own NK cells into mlNK cells. In patients, INKmune™ primed tumor killing NK cells have persisted for more than 100 days. These cells function in the hypoxic TME because due to upregulated nutrient receptors and mitochondrial survival proteins. INKmune™ is a patient friendly drug treatment that does not require pre-medication, conditioning or additional cytokine therapy to be given to the patients. INKmune™ is easily transported, stored and delivered to the patient by a simple intravenous infusion as an out-patient. INKmune™ is tumor agnostic; it can be used to treat many types of NK-resistant tumors including leukemia, lymphoma, myeloma, lung, ovarian, breast, renal and nasopharyngeal cancer. INKmune™ is treating patients in an open label Phase I/II trial in metastatic castration-resistant prostate cancer in the US this year. About INmune Bio Inc. INmune Bio Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat cancer (INB03™), Early Alzheimer’s disease and treatment-resistant depression (XPro™). The Natural Killer Cell Priming Platform includes INKmune™ developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer. INmune Bio’s product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com. Forward-Looking Statements Clinical trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. INB03™, XPro1595 (XPro™), and INKmune™ are still in clinical trials or preparing to start clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to produce more drug for clinical trials; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in the Company’s filings with the Securities and Exchange Commission, including the Company’s Annual Report on Form 10-K, the Company’s Quarterly Reports on Form 10-Q and the Company’s Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. INmune Bio Contact:David Moss, CFO (858) 964-3720info@inmunebio.com Investor Contact:Jason NelsonCore IR(516) 842-9619 x-823 The following tables summarize our results of operations for the periods indicated: INMUNE BIO INC.CONDENSED CONSOLIDATED BALANCE SHEETS(In thousands, except share and per share amounts)(Unaudited) March 31,2024 December 31,2023 ASSETS CURRENT ASSETS Cash and cash equivalents $26,002 $35,848 Research and development tax credit receivable 2,133 1,905 Other tax receivable 557 537 Prepaid expenses and other current assets 1,109 1,510 Prepaid expenses – related party 23 142 TOTAL CURRENT ASSETS 29,824 39,942 Operating lease – right of use asset 389 414 Other assets 106 131 Acquired in-process research and development intangible assets 16,514 16,514 TOTAL ASSETS $46,833 $57,001 LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS’ EQUITY CURRENT LIABILITIES Accounts payable and accrued liabilities $9,294 $7,901 Accounts payable and accrued liabilities – related parties 56 35 Deferred liabilities 520 489 Current portion of long-term debt 7,455 9,921 Operating lease, current liabilities 125 119 TOTAL CURRENT LIABILITIES 17,450 18,465 Long-term operating lease liability 360 397 TOTAL LIABILITIES 17,810 18,862 COMMITMENTS AND CONTINGENCIES Redeemable common stock, $0.001 par value; 75,697 issued and outstanding, respectively (Note 9) 799 799 STOCKHOLDERS’ EQUITY Preferred stock, $0.001 par value, 10,000,000 shares authorized, 0 shares issued and outstanding - - Common stock, $0.001 par value, 200,000,000 shares authorized, 17,950,776 shares issued and outstanding, respectively 18 18 Additional paid-in capital 160,922 159,143 Accumulated other comprehensive loss (669) (799)Accumulated deficit (132,047) (121,022)TOTAL STOCKHOLDERS’ EQUITY 28,224 37,340 TOTAL LIABILITIES, REDEEMABLE COMMON STOCK AND STOCKHOLDERS’ EQUITY $46,833 $57,001 INMUNE BIO INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(In thousands, except share and per share amounts)(Unaudited) For the Three Months EndedMarch 31, 2024 2023 REVENUE $14 $38 OPERATING EXPENSES General and administrative 2,338 2,328 Research and development 8,693 4,133 Total operating expenses 11,031 6,461 LOSS FROM OPERATIONS (11,017) (6,423) OTHER EXPENSE, NET (8) (113) NET LOSS $(11,025) $(6,536) Net loss per common share – basic and diluted $(0.61) $(0.36) Weighted average common shares outstanding – basic and diluted 18,026,473 17,945,995 COMPREHENSIVE LOSS Net loss $(11,025) $(6,536)Other comprehensive income (loss) – foreign currency translation 130 (9)Total comprehensive loss $(10,895) $(6,545) INMUNE BIO INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(In thousands)(Unaudited) For the Three Months EndedMarch 31, 2024 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Net loss $(11,025) $(6,536)Adjustments to reconcile net loss to net cash used in operating activities: Stock-based compensation 1,779 1,737 Accretion of debt discount 34 67 Changes in operating assets and liabilities: Research and development tax credit receivable (228) 6,285 Other tax receivable (20) (34)Prepaid expenses 401 394 Prepaid expenses – related party 119 (1)Other assets 25 - Accounts payable and accrued liabilities 1,393 (3,129)Accounts payable and accrued liabilities – related parties 21 - Deferred liabilities 31 (25)Accrued liability – long-term - 88 Operating lease liabilities (6) 13 Net cash used in operating activities (7,476) (1,141) CASH FLOWS FROM FINANCING ACTIVITIES: Repayments of debt (2,500) - Net used in financing activities (2,500) - Impact on cash from foreign currency translation 130 (9) NET DECREASE IN CASH AND CASH EQUIVALENTS (9,846) (1,150)CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 35,848 52,153 CASH AND CASH EQUIVALENTS AT END OF PERIOD $26,002 $51,003 SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION: Cash paid for income taxes $- $- Cash paid for interest expense $302 $450

▎药明康德内容团队编辑本期看点1. 治疗特应性皮炎的选择性肽疗法si-544的1b期临床试验结果积极，75%的患者的临床症状有客观改善。2. 下一代精准靶向疗法XPro使两名阿尔茨海默病患者的认知功能保持稳定超过3年。3. 美国FDA批准了在研先导编辑（prime editing）疗法PM359用于治疗慢性肉芽肿病（CGD）的IND申请，标志新一代基因编辑技术临床转化的重要里程碑。药明康德内容团队整理si-544：公布1b期临床试验数据selectION公司公布了其候选药物si-544在轻度至重度特应性皮炎患者中的1b期临床试验数据。si-544是一种选择性经优化的多肽疗法，可阻断离子通道Kv1.3。Kv1.3是一种参与效应记忆T（TEM）细胞激活和增殖的特殊离子通道。TEM细胞是许多自身免疫性疾病（如特应性皮炎、银屑病、类风湿性关节炎或多发性硬化）及某些罕见癌症（如淋巴瘤）的根源。在临床前研究中，si-544表现出了良好的疗效。该候选疗法通过在功能上抑制和消除疾病特异性、慢性激活的TEM细胞，同时保持完全的免疫能力，有望解决重大的未竟医疗需求。此次公布的结果显示，si-544的耐受性良好，没有观察到严重的不良反应、剂量限制毒性或安全信号。在接受si-544治疗的患者中，75%的患者的临床症状得到了客观改善，其中44%的患者在监测期结束时，皮肤变得光洁或接近光洁。用药后，这种改善的趋势维持了整个监测期。XPro：公布1b期临床试验中两名患者的数据INmune Bio公司公布了两名在完成1b期试验后继续接受XPro治疗超过3年的阿尔茨海默病患者的最新情况。XPro是一款旨在中和可溶性肿瘤坏死因子（TNF）的下一代精准靶向疗法。该候选疗法不会干扰促进正常功能和修复的TNF形式，这种特异性大大提高了有效性和安全性。两名阿尔茨海默病患者在完成为期3个月的开放标签试验和12个月的扩展试验后，在澳大利亚同情使用计划下继续接受XPro治疗超过三年。此次公布的结果显示，XPro长期给药的安全性和耐受性良好，这些患者已在持续的XPro治疗中保持稳定的认知功能超过3年。PM359：IND申请获得FDA许可Prime Medicine公司宣布，该公司为在研先导编辑疗法PM359递交的IND申请已经获得美国FDA的许可，用于治疗慢性肉芽肿病。这使该公司能够启动全球性的1/2期临床试验。新闻稿指出，这是先导编辑技术首个获得许可的IND，标着新一代基因编辑技术临床转化的重要里程碑。PM359是Prime Medicine在血液学和免疫学领域的首个候选疗法，针对的是慢性肉芽肿病的p47phox变体。PM359通过先导编辑器在体外修改自体造血干细胞（HSCs）。临床前研究显示，这些编辑器可以高效率纠正携带病因突变细胞的DNA。PM359已获得美国FDA授予的罕见儿科药物认定和孤儿药资格。二价诺如病毒候选疫苗：公布1期临床试验数据Vaxart公司公布了其口服二价诺如病毒候选疫苗片剂的1期临床试验的顶线结果。该候选疫苗的使用对象是处于哺乳期的母亲，旨在通过母乳将诺如病毒抗体从母体转移到婴儿，从而潜在地提高婴儿对诺如病毒感染的抵抗力。研究人员在这项研究中观察到哺乳期的母亲及其母乳中的抗体升高。在高剂量组母亲的母乳中，针对诺如病毒GI.1病毒株的抗体平均升高了4.0倍，针对GII.4病毒株的抗体平均升高6.0倍。安全性方面，没有出现与疫苗相关的严重不良事件，也没有出现剂量限制性药理毒性。LTI-03：公布1b期临床试验的初步数据Aileron Therapeutics公司公布了其用于治疗特发性肺纤维化（IPF）吸入性疗法LTI-03的1b期临床试验数据。LTI-03是一种新型的Caveolin-1相关多肽，由7个氨基酸组成，可抑制促纤维化信号传导并帮助关键上皮细胞存活。此次公布的结果显示，LTI-03低剂量组患者在接受治疗后，病理性基底样细胞和成纤维细胞中多种促纤维化蛋白的表达降低，与上皮健康相关生物标志物的表达增加。作为评估指标的8种生物标志物中，有7种表现出了积极趋势，其中3种具有统计学意义。安全性方面，低剂量LTI-03的耐受性良好，未观察到安全信号。LTI-03高剂量组的数据预计将于2024年第三季度公布。REM-422：两项1期临床试验完成首批患者给药Remix Therapeutics公司宣布，其潜在“first-in-class”的MYB mRNA降解剂REM-422的两项1期临床试验均已完成首批患者给药。MYB是多种实体瘤和血液恶性肿瘤的致癌驱动因子。REM-422是一种强效、选择性口服小分子mRNA降解剂，通过促进mRNA转录本掺入毒性外显子，引发无义介导的mRNA降解（NMD），可减少MYB mRNA及随后的蛋白表达，从而在MYB依赖性人类肿瘤模型中产生抗肿瘤活性。目前，REM-422正在一项针对复发或转移性腺样囊性癌（ACC）患者的1期临床试验和一项针对复发/难治性急性髓系白血病（AML）或高危骨髓增生异常综合征（MDS）患者的1期临床试验中接受评估。该公司还宣布，美国FDA授予了REM-422孤儿药资格，用于治疗ACC和AML。SNK01：IND申请获得FDA许可NKGen Biotech公司宣布，美国FDA已批准其在研自然杀伤（NK）细胞疗法SNK01用于治疗帕金森病的IND申请。SNK01是一款自体、非基因工程改造的NK细胞产品。它具有增强的细胞毒性和激活性受体的表达，有望成为治疗帕金森病的一种新方法。该公司预计将于2024年下半年启动针对帕金森病的1期临床试验。PRAME TCR/IL-15 NK（SY-307）：IND申请获得FDA许可Replay公司和MD安德森癌症中心共同宣布，美国FDA已批准PRAME TCR/IL-15 NK（SY-307）的IND申请。PRAME TCR/IL-15 NK（SY-307）是一种由脐带血NK细胞开发而成的，用于治疗复发/难治性髓系恶性肿瘤的工程化T细胞受体（TCR）NK细胞疗法。这些细胞表达针对PRAME肿瘤相关新抗原的高亲和力TCR。PRAME具高免疫原性，在多种不同类型的癌症中都有表达，包括AML和MDS等血液系统恶性肿瘤，以及黑色素瘤、肉瘤、卵巢癌、子宫内膜癌、肺癌和乳腺癌等实体瘤。该候选疗法用于治疗复发/难治性AML和MDS患者的1/2期研究预计将于2024年第三季度启动。INNA-051：IND申请获得FDA许可ENA Respiratory公司宣布，美国FDA已批准其新型toll样受体2/6（TLR2/6）激动剂INNA-051干粉制剂的IND申请。INNA-051是一种不受病毒类型限制的鼻内抗病毒宿主防御免疫调节剂，是TLR2/6的强效潜在“first-in-class”激动剂。TLR2/6在识别病原体和触发先天性免疫反应中发挥着关键作用。此前，ENA Respiratory公司在流感模型中进行的2a期研究结果表明，INNA-051液体制剂能加速病毒清除并局部激发宿主的抗病毒防御能力。在此基础上，该公司开发了改进的干粉制剂，旨在为呼吸道病毒感染高危人群（包括老年人、患有基础疾病的人和有职业风险的人）提供一种方便的、每周仅需使用一次的鼻腔给药产品，以预防与呼吸道病毒感染相关的并发症。▲欲了解更多前沿技术在生物医药产业中的应用，请长按扫描上方二维码，即可访问“药明直播间”，观看相关话题的直播讨论与精彩回放参考资料（可上下滑动查看）[1] selectION Announces Positive Results from Phase 1b Clinical Trial Evaluating si-544 in Patients with Atopic Dermatitis. Retrieved April 30, 2024, from https://www.globenewswire.com/news-release/2024/04/29/2870968/0/en/selectION-Announces-Positive-Results-from-Phase-1b-Clinical-Trial-Evaluating-si-544-in-Patients-with-Atopic-Dermatitis.html[2] ENA Respiratory Announces FDA IND Clearance for its Prophylactic Intranasal INNA-051 - a First-in-Class Antiviral Innate Immunomodulator. Retrieved April 30, 2024, from https://www.globenewswire.com/news-release/2024/04/29/2870969/0/en/ENA-Respiratory-Announces-FDA-IND-Clearance-for-its-Prophylactic-Intranasal-INNA-051-a-First-in-Class-Antiviral-Innate-Immunomodulator.html[3] Prime Medicine Announces FDA Clearance of Investigational New Drug (IND) Application for PM359 for the Treatment of Chronic Granulomatous Disease (CGD). Retrieved April 30, 2024, from https://www.globenewswire.com/news-release/2024/04/29/2871079/0/en/Prime-Medicine-Announces-FDA-Clearance-of-Investigational-New-Drug-IND-Application-for-PM359-for-the-Treatment-of-Chronic-Granulomatous-Disease-CGD.html[4] Replay[5] Terns Pharmaceuticals Announces Data from Ongoing Phase 1 Pharmacokinetic Study of Allosteric BCR-ABL Inhibitor TERN-701 in Adult Healthy Volunteers and Highlights Potential for Competitive Differentiation. Retrieved April 30, 2024, from https://www.globenewswire.com/news-release/2024/04/29/2871639/0/en/Terns-Pharmaceuticals-Announces-Data-from-Ongoing-Phase-1-Pharmacokinetic-Study-of-Allosteric-BCR-ABL-Inhibitor-TERN-701-in-Adult-Healthy-Volunteers-and-Highlights-Potential-for-Co.html[6] Bitterroot Bio Announces Dosing of First Participants in a Phase 1, First-in-Human Study of BRB-002 in Healthy Volunteers. Retrieved April 30, 2024, from https://www.globenewswire.com/news-release/2024/04/29/2871160/0/en/Bitterroot-Bio-Announces-Dosing-of-First-Participants-in-a-Phase-1-First-in-Human-Study-of-BRB-002-in-Healthy-Volunteers.html[7] Replay and MD Anderson announce FDA clearance of IND application for first-in-class PRAME-targeted T-Cell Receptor Natural Killer (TCR-NK) cell therapy for hematological malignancies. Retrieved April 30, 2024, from https://www.globenewswire.com/news-release/2024/04/30/2872029/0/en/Replay-and-MD-Anderson-announce-FDA-clearance-of-IND-application-for-first-in-class-PRAME-targeted-T-Cell-Receptor-Natural-Killer-TCR-NK-cell-therapy-for-hematological-malignancies.html[8] Aileron Therapeutics Announces Positive Data from Cohort 1 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF). Retrieved May 1, 2024, from https://www.globenewswire.com/news-release/2024/05/01/2873251/28652/en/Aileron-Therapeutics-Announces-Positive-Data-from-Cohort-1-of-the-Phase-1b-Clinical-Trial-of-LTI-03-in-Idiopathic-Pulmonary-Fibrosis-IPF.html[9] Context Therapeutics Announces FDA Clearance of IND Application for a Phase 1 Clinical Trial of CTIM-76. Retrieved May 6, 2024, from https://www.globenewswire.com/news-release/2024/05/02/2874098/0/en/Context-Therapeutics-Announces-FDA-Clearance-of-IND-Application-for-a-Phase-1-Clinical-Trial-of-CTIM-76.html[10] Ventus Therapeutics Announces First Participant Dosed in Clinical Study with an NLRP3 Inhibitor Licensed Exclusively to Novo Nordisk. Retrieved May 6, 2024, from https://www.businesswire.com/news/home/20240430835089/en[11] Arsenal Biosciences Announces First Patient Dosed in Phase 1/2 Clinical Trial of AB-2100 in Development as a Treatment for Clear-cell Renal Cell Carcinoma. Retrieved May 6, 2024, from https://www.businesswire.com/news/home/20240430131934/en/[12] Foresee Pharmaceuticals Announces First Subject Dosed in its First-in-Human Clinical Trial of FP-020. Retrieved May 6, 2024, from https://www.prnewswire.com/news-releases/foresee-pharmaceuticals-announces-first-subject-dosed-in-its-first-in-human-clinical-trial-of-fp-020-302131320.html[13] Aurion Biotech Announces Completion of Enrollment in Phase 1 / 2 Clinical Trial. Retrieved May 6, 2024, from https://www.businesswire.com/news/home/20240430312515/en[14] Alumis Announces First Participant Dosed in Phase 1 Clinical Trial of CNS Penetrant Allosteric TYK2 Inhibitor A-005. Retrieved May 6, 2024, from https://www.globenewswire.com/en/news-release/2024/04/30/2872215/0/en/Alumis-Announces-First-Participant-Dosed-in-Phase-1-Clinical-Trial-of-CNS-Penetrant-Allosteric-TYK2-Inhibitor-A-005.html[15] Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition. Retrieved May 6, 2024, from https://www.businesswire.com/news/home/20240430915822/en[16] IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757. Retrieved May 6, 2024, from https://irlab.se/mfn_news/irlab-has-received-approval-from-the-swedish-medical-products-agency-to-conduct-a-phase-i-study-of-the-drug-candidate-irl757/[17] Remix Therapeutics Announces First Patients Dosed in Two Phase 1 Clinical Trials Investigating REM-422 for Treatment of Adenoid Cystic Carcinoma (ACC) and Acute Myeloid Leukemia/Myelodysplastic Syndromes (AML/MDS). Retrieved May 6, 2024, from https://www.prnewswire.com/news-releases/remix-therapeutics-announces-first-patients-dosed-in-two-phase-1-clinical-trials-investigating-rem-422-for-treatment-of-adenoid-cystic-carcinoma-acc-and-acute-myeloid-leukemiamyelodysplastic-syndromes-amlmds-302133787.html[18] INmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three Years. Retrieved May 6, 2024, from https://www.inmunebio.com/index.php/newsroom/2024-news/muneioncrovidespdateonwoatientsfromtheha20240430050503[19] Vaxart Announces Positive Results for Its Bivalent Norovirus Vaccine Candidate in Lactating Mothers. Retrieved May 6, 2024, from https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-positive-results-its-bivalent-norovirus-vaccine免责声明：药明康德内容团队专注介绍全球生物医药健康研究进展。本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：本文来自药明康德内容团队，欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，聚焦全球生物医药健康创新